This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Roche Tcrc Inc.. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: David Carlile and His Patent in Bispecific Antibody Treatment.
Introduction
David Carlile is an inventor associated with Princes Risborough, Great Britain. His listed patent work concerns dosing for treatment with an anti-CD20/anti-CD3 bispecific antibody.
Latest Patents
Carlile is credited with 1 patent: “Dosing for Treatment with Anti-CD20/Anti-CD3 Bispecific Antibody.” The patent addresses dosing in a treatment approach involving a bispecific antibody.
Career Highlights
The available information associates Carlile with Roche TCRC Inc. and identifies his patent activity in the field of antibody-based treatment. No further career details are provided.
Collaborations
Carlile’s listed coworkers include Axel Boehnke and Martin Weisser. Their names are associated with his professional and patent-related context.
Conclusion
David Carlile’s recorded innovation is a patent focused on dosing for anti-CD20/anti-CD3 bispecific antibody treatment, reflecting his connection to Roche TCRC Inc. and collaborative work with fellow researchers.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile